Theranyx, the French biotech leader in functional antibody fragment discovery announced the completion of its first round of convertible bonds with privet investors for 400 K€. This initial successful funding has been concluded through Savile Capital, a family office operating in Luxembourg.
The new funding will enable Theranyx to speed-up its internal pipeline development for the discovery of new cancer treatments and increase its capacity to raise extra funds from BPI France (French public investment bank) in a near future.
“ Theranyx has a very ambitious research program this year with a total of 20 targets in the pipeline, half of which concerning external collaborations. This new funding will be very helpful for us to reach our research objectives in 2016 by doubling the number of researchers working in our laboratory” declared Etienne L’Hermite, CEO of the company.
About Savile Capital:
Savile Capital is a multi-family office and investment firm based in Luxembourg and dedicated to entrepreneurs and innovation. We aim at connecting smart investors and innovative entrepreneurs to leverage value. Our ecosystem of high-end skills and breaking-through expertise provides our clients the ideal plug to drive and deploy their professional and private assets. Our areas of services is comprised of three interdependent pillars : Family Office, Advisory and Investment.
Theranyx, based in Marseille (Fr), is leading drug Discovery Company involved in the generation of functional antibody fragments, named Therabodies, targeting integral membrane receptors such as GPCRs and Ion Channels. Therabodies’ applications include target validation, diagnostics, therapeutic use and ADC. Theranyx business model is including both shared risk collaboration with biotech and pharma leaders and internal pipeline development on novel targets in cancer indications.
For further information, do not hesitate to contact us : email@example.com…